uniQure N.V. (0EE0.L)
USD 8.57
(4.71%)
USD 8.57
(4.71%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 130.06 Million USD | -3.3% |
| 2022 | 134.51 Million USD | 3.51% |
| 2021 | 129.95 Million USD | 96.83% |
| 2020 | 66.02 Million USD | -1.75% |
| 2019 | 67.19 Million USD | 89.44% |
| 2018 | 35.47 Million USD | 93.55% |
| 2017 | 18.32 Million USD | -6.64% |
| 2016 | 19.63 Million USD | 33.66% |
| 2015 | 14.68 Million USD | -27.03% |
| 2014 | 20.12 Million USD | 121.05% |
| 2013 | 9.1 Million USD | 1430.0% |
| 2012 | 595.12 Thousand USD | 155.1% |
| 2011 | 233.29 Thousand USD | -20.63% |
| 2010 | 293.92 Thousand USD | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q3 | 63.29 Million USD | -90.14% |
| 2024 Q2 | 518.44 Million USD | 2.15% |
| 2024 Q1 | 507.51 Million USD | 398.79% |
| 2023 Q2 | 131.3 Million USD | -2.25% |
| 2023 FY | 130.06 Million USD | -3.3% |
| 2023 Q1 | 134.32 Million USD | -0.14% |
| 2023 Q4 | 130.06 Million USD | -0.26% |
| 2023 Q3 | 130.4 Million USD | -0.68% |
| 2022 Q1 | 129.65 Million USD | -0.23% |
| 2022 FY | 134.51 Million USD | 3.51% |
| 2022 Q4 | 134.51 Million USD | 1.68% |
| 2022 Q3 | 132.28 Million USD | -0.24% |
| 2022 Q2 | 132.61 Million USD | 2.28% |
| 2021 Q1 | 99.95 Million USD | 51.4% |
| 2021 Q3 | 101.22 Million USD | -0.09% |
| 2021 Q4 | 129.95 Million USD | 28.38% |
| 2021 FY | 129.95 Million USD | 96.83% |
| 2021 Q2 | 101.31 Million USD | 1.36% |
| 2020 Q2 | 65.65 Million USD | -1.61% |
| 2020 FY | 66.02 Million USD | -1.75% |
| 2020 Q1 | 66.72 Million USD | -0.7% |
| 2020 Q4 | 66.02 Million USD | 0.29% |
| 2020 Q3 | 65.82 Million USD | 0.27% |
| 2019 Q4 | 67.19 Million USD | 0.04% |
| 2019 Q3 | 67.17 Million USD | -0.72% |
| 2019 FY | 67.19 Million USD | 89.44% |
| 2019 Q1 | 58.97 Million USD | 66.26% |
| 2019 Q2 | 67.65 Million USD | 14.72% |
| 2018 Q4 | 35.47 Million USD | 269.61% |
| 2018 Q3 | 9.59 Million USD | -25.26% |
| 2018 Q2 | 12.84 Million USD | -21.56% |
| 2018 Q1 | 16.36 Million USD | -17.08% |
| 2018 FY | 35.47 Million USD | 93.55% |
| 2017 FY | 18.32 Million USD | -6.64% |
| 2017 Q3 | 14.35 Million USD | -11.14% |
| 2017 Q1 | 17.92 Million USD | -8.72% |
| 2017 Q4 | 19.74 Million USD | 37.54% |
| 2017 Q2 | 16.15 Million USD | -9.86% |
| 2016 Q3 | 20.46 Million USD | 0.25% |
| 2016 FY | 19.63 Million USD | 33.66% |
| 2016 Q2 | 20.41 Million USD | 51.91% |
| 2016 Q1 | 13.44 Million USD | -8.48% |
| 2016 Q4 | 19.63 Million USD | -4.1% |
| 2015 Q2 | 16.97 Million USD | -8.53% |
| 2015 FY | 14.68 Million USD | -27.03% |
| 2015 Q4 | 14.68 Million USD | -1.95% |
| 2015 Q3 | 14.97 Million USD | -11.77% |
| 2015 Q1 | 18.56 Million USD | -7.78% |
| 2014 Q4 | 20.12 Million USD | 0.01% |
| 2014 Q2 | 20.07 Million USD | 145.61% |
| 2014 Q3 | 20.12 Million USD | 0.24% |
| 2014 Q1 | 8.17 Million USD | -10.22% |
| 2014 FY | 20.12 Million USD | 121.05% |
| 2013 Q1 | - USD | -100.0% |
| 2013 Q2 | 9.92 Million USD | 0.0% |
| 2013 Q4 | 9.1 Million USD | -11.6% |
| 2013 Q3 | 10.29 Million USD | 3.83% |
| 2013 FY | 9.1 Million USD | 1430.0% |
| 2012 Q4 | 595.12 Thousand USD | 0.0% |
| 2012 FY | 595.12 Thousand USD | 155.1% |
| 2011 FY | 233.29 Thousand USD | -20.63% |
| 2010 FY | 293.92 Thousand USD | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Agios Pharmaceuticals, Inc. | 56.98 Million USD | -128.232% |
| Amicus Therapeutics, Inc. | 387.85 Million USD | 66.466% |
| Atara Biotherapeutics, Inc. | 45.69 Million USD | -184.65% |
| bluebird bio, Inc. | 224.41 Million USD | 42.044% |
| Cara Therapeutics, Inc. | 37.07 Million USD | -250.778% |
| Imunon, Inc. | 1.13 Million USD | -11316.291% |
| Editas Medicine, Inc. | 24.37 Million USD | -433.666% |
| IQVIA Holdings Inc. | 12.95 Billion USD | 98.996% |
| Mettler-Toledo International Inc. | 1.97 Billion USD | 93.416% |
| Myriad Genetics, Inc. | 130.9 Million USD | 0.638% |
| Neurocrine Biosciences, Inc. | 258.3 Million USD | 49.646% |
| Supernus Pharmaceuticals, Inc. | 33.19 Million USD | -291.809% |
| Verastem, Inc. | 40.08 Million USD | -224.465% |
| Walgreens Boots Alliance, Inc. | 8.04 Billion USD | 98.383% |
| Waters Corporation | 2.3 Billion USD | 94.359% |
| Thermo Fisher Scientific Inc. | 31.3 Billion USD | 99.585% |
| Biogen Inc. | 7.18 Billion USD | 98.191% |
| Nektar Therapeutics | 112.62 Million USD | -15.485% |
| Perrigo Company plc | 3.63 Billion USD | 96.42% |
| Dynavax Technologies Corporation | 252.41 Million USD | 48.472% |
| Illumina, Inc. | 1.48 Billion USD | 91.265% |
| Corbus Pharmaceuticals Holdings, Inc. | 3.23 Million USD | -3916.049% |
| Iovance Biotherapeutics, Inc. | 1 Million USD | -12906.5% |
| Heron Therapeutics, Inc. | 173.75 Million USD | 25.144% |
| Unity Biotechnology, Inc. | 23.53 Million USD | -452.551% |
| BioMarin Pharmaceutical Inc. | 593.09 Million USD | 78.07% |
| Sangamo Therapeutics, Inc. | 33.51 Million USD | -288.08% |
| Evolus, Inc. | 120.35 Million USD | -8.064% |
| Adicet Bio, Inc. | 17.7 Million USD | -634.706% |
| Aclaris Therapeutics, Inc. | 3.07 Million USD | -4131.132% |
| Regeneron Pharmaceuticals, Inc. | 2.7 Billion USD | 95.188% |
| Esperion Therapeutics, Inc. | 501.54 Million USD | 74.067% |
| FibroGen, Inc. | 89.69 Million USD | -45.005% |
| Agilent Technologies, Inc. | 2.73 Billion USD | 95.244% |
| OPKO Health, Inc. | 222.03 Million USD | 41.421% |
| Homology Medicines, Inc. | 43.17 Million USD | -201.244% |
| Geron Corporation | 35.05 Million USD | -271.074% |
| Alnylam Pharmaceuticals, Inc. | 2.34 Billion USD | 94.449% |
| Exelixis, Inc. | 189.94 Million USD | 31.525% |
| Viking Therapeutics, Inc. | 936 Thousand USD | -13795.833% |
| Anavex Life Sciences Corp. | - USD | -Infinity% |
| Intellia Therapeutics, Inc. | 96.74 Million USD | -34.438% |
| Zoetis Inc. | 6.56 Billion USD | 98.019% |
| Axsome Therapeutics, Inc. | 178.07 Million USD | 26.958% |
| Abeona Therapeutics Inc. | 4.4 Million USD | -2854.68% |
| Vertex Pharmaceuticals Incorporated | 724.7 Million USD | 82.053% |
| Kala Pharmaceuticals, Inc. | 34.19 Million USD | -280.418% |
| Ionis Pharmaceuticals, Inc. | 1.4 Billion USD | 90.712% |
| Sarepta Therapeutics, Inc. | 1.13 Billion USD | 88.515% |
| Corcept Therapeutics Incorporated | - USD | -Infinity% |
| Halozyme Therapeutics, Inc. | 1.49 Billion USD | 91.325% |
| Blueprint Medicines Corporation | 610.96 Million USD | 78.711% |
| Insmed Incorporated | 1.19 Billion USD | 89.101% |
| TG Therapeutics, Inc. | 100.11 Million USD | -29.912% |
| Incyte Corporation | 29.16 Million USD | -346.009% |
| Emergent BioSolutions Inc. | 446.5 Million USD | 70.87% |